Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Jun 1 2023

Hepatitis B Virus

Images graph.jpg
  • Snapshot
    • A 35-year-old presents to the emergency department due to abdominal pain and malaise. He also reports "yellow-ing" of his skin. Medical history is noncontributory. Social history is notable for intravenous drug use and having multiple sexual partners. Physical examination is remarkable for right upper quadrant tenderness, generalized jaundice, and scleral icterus. Laboratory studies demonstrate the presence of HBsAg and significantly elevated IgM anti-HBc, and HBeAg.
  • Introduction
    • Classification
      • a Hepadnavirus in the Hepadnaviridae family
        • circular, partially double-stranded DNA virus
    • Epidemiology
      • risk factors
        • not receiving hepatitis B virus (HBV) vaccine
        • sexual contact with a person with HBV
        • illicit drug use
        • having HIV and hepatitis C virus
    • Transmission
      • perinatal transmission
      • blood transfusion
      • transplant
      • sexual contact
      • blood exposure
    • Pathogenesis
      • once the HBV is in the bloodstream, it makes its way to the liver, where it replicates within hepatocytes, causing immune-mediated hepatitis via CD8+ T-cells and natural killer cells
      • when HBV is inside the hepatocyte, the viral genome enters the hepatocyte nucleus
        • the positive strand of the HBV DNA is synthesized and is converted to covalently closed, circular DNA (cccDNA)
          • the HBV genome undergoes reverse transcription, creating a pre-genomic RNA, which becomes encapsidated
            • a new negative and subsequent positive strand of the HBV DNA is eventually synthesized
              • the partially double-stranded HBV DNA nucleocapsid can enter more hepatocytes to produce more cccDNA
    • Prognosis
      • most immunocompetent adult patients spontaneously recover
        • 90% of infected adults recover, 10% progress to chronic infection
      • most neonates progress to chronic infection
      • worse prognosis with coinfection with hepatitis D or hepatitis C infection
  • Presentation
    • Symptoms
      • acute hepatitis
        • anorexia
        • nausea
        • right upper quadrant pain
      • chronic hepatitis
        • many are asymptomatic
        • fatigue
    • Physical exam
      • acute hepatitis
        • jaundice and scleral icterus
          • typically resolves in 1-3 months
      • chronic hepatitis
        • normal
        • may have stigmata of chronic liver disease
          • e.g., spider angiomata, ascites, and asterixis
        • extrahepatic manifestations
          • polyarteritis nodosa
          • membranous nephropathy (leading to nephrotic range proteinuria)
            • and less commonly, membranoproliferative glomerulonephropathy
          • aplastic anemia
  • Studies
    • Liver function tests
      • Alanine/aspartate aminotransferases (ALT/AST)
        • Elevation in the acute phase of up to 1,000 to 2,000 U/L
        • Milder elevations or can be normal in the chronic phase
    • Serologic studies
      • HBsAg
        • indicates that there is an HBV infection
      • anti-HBs
        • indicates immunity to HBV infection via
          • prior infection
          • vaccination
      • HBcAg
        • an antigen associated with the core of the HBV
      • anti-HBc
        • IgM antibodies against HBc suggests an acute or recent infection
        • IgG antibodies against HBc suggest a previous exposure or chronic infection
        • during the window period, may be the only positive serologic test suggesting infection
      • HBeAg
        • infected hepatocytes secrete this antigen, suggesting active replication, thus having high transmissibility
      • anti-HBe
        • suggest low transmissibility
  • Differential
    • Hepatitis A infection
      • differentiating factor
        • presence of anti-hepatitis A antibodies in serological testing
    • Hepatitis C infection
      • differentiating factor
        • presence of anti-hepatitis C antibodies in serological testing
  • Treatment
    • Medical
      • vaccination
        • indication
          • as a preventative measure against HBV infection
            • all neonates
            • all unvaccinated infants, children, and adolescents
            • all unvaccinated adults with an increased risk of contracting the infection
              • healthcare personnel
              • a sexually-active person with multiple sexual partners
              • end-stage renal disease
              • HIV infection
              • chronic liver disease
      • tenofovir or entecavir
        • indication
          • monotherapy for acute HBV infection in patients with fulminant infection or severe acute hepatitis (e.g., increased INR)
          • monotherapy for chronic HBV infection with immune-active chronic hepatitis
            • HBeAg-positive
            • HBeAg-negative with elevated viral DNA levels and a transaminitis
          • patients with hepatocellular carcinoma
        • comments
          • acute HBV infection is usually symptomatically treated as most cases self-resolve
  • Complications
    • Superinfection with hepatitis D virus
    • Acute fulminant hepatic failure
    • Cirrhosis
    • Hepatocellular carcinoma
1 of 0
1 of 9
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options